English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Non‐small cell lung cancer (NSCLC) continues to be one of the major causes of cancer‐related deaths worldwide, and brain metastases are the major cause of death in NSCLC patients. With recent advances in understanding the underlying molecular mechanism of NSCLC development and progression, mutations in epidermal growth factor receptor ( EGFR ) have been recognized as a key predictor of therapeutic sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Using EGFR‐TKI alone or in combination with standard treatments such as whole‐brain radiotherapy and surgery has been an effective strategy for the management of brain metastasis. Particularly, a newer generation of EGFR‐TKIs, including osimertinib and AZD3759, has been developed. These new EGFR‐TKIs can cross the blood–brain barrier and potentially treat EGFR‐TKI resistance and improve prognosis. In this article, current progress and outcomes of clinical trials on the use of EGFR‐TKIs for treating NSCLC patients with brain metastasis will be reviewed.

chronic diseases and translational medicine

Current progress and outcomes of clinical trials on using epidermal growth factor receptor‐tyrosine kinase inhibitor therapy in non‐small cell lung cancer patients with brain metastases